The shelf is now live, so the company can file a prospectus supplement and launch an offering at any time. Traders should watch for a takedown announcement, which would likely be deeply dilutive at current prices. Given the distressed state, any offering below $1.00 per share could trigger delisting risk. Consider short-side positioning or avoiding the stock until the overhang clears.
Price Chart
Executive Summary
Traws Pharma's S-3 shelf registration (filing 333-297195) became effective on July 9, 2026, allowing the company to sell up to $139.2M in unsold securities — roughly 10.7x its current $10M market cap. With only $3.1M in cash, a stockholders' deficit, and a going-concern qualification, this activation enables immediate dilutive capital raises from a distressed position.
Key Facts
- Shelf registration (File No. 333-297195) became effective July 9, 2026
- Carries forward $139.2M in unsold securities from prior expiring shelf
- Market cap is ~$10M, making the shelf potential overhang ~10.7x current value
- Company had $3.1M cash and a stockholders' deficit of -$5.3M as of March 31, 2026
- Auditor included a going-concern qualification in the most recent annual report
Financial Impact
Shelf activation enables highly dilutive primary offerings; potential offering size is up to $139.2M vs. $10M market cap
Risk Factors
- Imminent dilutive equity offering likely at distressed prices
- Potential delisting if stock price falls below $1.00 (CBOE listing standards)
- Further cash burn may force bankruptcy if capital raise fails
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-002245 |
| Document: 9999999995-26-002245-index.html | 9999999995-26-002245 |
| Document: 9999999995-26-002245.txt | 9999999995-26-002245 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | S-1 | $0.3500 | awaiting T+20 | — | $0.3700 (−5.71%) |
Oct 23, 2026 4d ago | 8-K | $0.3411 | awaiting T+20 | — | $0.3700 (−8.47%) |
Oct 20, 2026 7d ago | DEFA14A | $0.3760 | awaiting T+20 | — | $0.3700 (−1.60%) |
Oct 20, 2026 7d ago | DEF 14A | $0.3760 | awaiting T+20 | — | $0.3700 (+1.60%) |
Aug 14, 2026 10w ago | Press Release | $0.5400 $0.5200 | ▲ +3.70% | ▲ +2.18% | $0.3700 (+31.48%) |
Jul 10, 2026 15w ago | 8-K | $0.6849 $0.5400 | ▲ +21.16% | ▲ +24.34% | $0.3700 (+45.98%) |
Jul 10, 2026 15w ago | 424B5 | $0.6849 $0.5400 | ▲ +21.16% | ▲ +24.34% | $0.3700 (+45.98%) |
Jul 10, 2026 15w ago | EFFECT | $0.7600 $0.5320 | ▲ +30.00% | ▲ +32.43% | $0.3700 (+51.32%) |
Jul 9, 2026 15w ago | 8-K | $0.7600 $0.5320 | ▼ −30.00% | ▼ −32.43% | $0.3700 (−51.32%) |
Jul 1, 2026 16w ago | S-3 | $0.7677 $0.4411 | ▼ −42.54% | ▼ −42.13% | $0.3700 (−51.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers